New target discovered to treat epileptic seizures following brain trauma...( New therapies for some forms of epil...),Health
New therapies for some forms of epilepsy may soon be possible, thanks to a discovery made by a team of University of British Columbia and Vancouver Coastal Health Research Institute neuroscience researchers.
The researchers found that hemichannels - the same channels the researchers previously found to that cause cell death following a stroke - may also cause epileptic seizures that occur following head trauma or a stroke.
The findings, published tomorrow in Science, will allow researchers to focus on new treatments that block these channels. A hemichannel is a channel that can form in nerve cells which allows chemical ions to pass through.
"The glutamate receptor that is linked to cell death following a stroke also triggers opening of hemichannels," says UBC Psychiatry Prof. Brian MacVicar, who is a member of the Brain Research Centre at UBC and VCH Research Institute. "Therefore both stroke itself or the glutamate released by a stroke can open hemichannels and cause cell death or epileptic seizures."
The researchers tested the effect of glutamate at levels less than those reached during stroke and found that more moderate activation of glutamate receptors opens hemichannels and causes seizure but does not produce cell death associated with stroke.
Glutamate is one of the brain's most abundant chemical messengers. Gap junctions are connections that allow molecules and ions, to flow between cells. Junctions are composed of two hemichannels that bridge intercellular space.
When epileptic seizures occur, hemichannels unexpectedly open near the synapses, which disrupt the normal electrical activity of the brain leading to seizures.
"We found that blocking hemichannels reduced the epilepsy-like discharges," says Roger Thompson, a former UBC Psychiatry post-doctoral Fellow who is now an Assistant Professor of Cell Biology, Anatomy and Clinical Neurosciences at the University of Calgary.
'/>"/>
| Contact: Catherine Loiacono catherine.loiacono@ubc.ca 604-822-2644 University of British Columbia Source:Eurekalert |
Related medicine news :
1. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
2. NHHF Scholarship Program Targets Growing Demand for Diversity Among Health Care Professionals
3. WHO tool helps target bone treatment
4. Broccoli compound targets key enzyme in late-stage cancer
5. New breast imaging technology targets hard-to-detect cancers
6. IDO2 an active enzyme to target in pancreatic cancer
7. Experts: Targeted agricultural investments will yield high results, slash poverty in Africa
8. Combining targeted therapy drugs may treat previously resistant tumors
9. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
10. UCSD researchers identify potential new drug target for chronic leukemia
11. TargetScan Evaluation is Shown to Deliver Potentially Higher Cancer Detection Rate and More Accurate Assessment of Grade
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |